Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.
According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050.
The global Myelodysplastic Syndrome (MDS) Treatment market is valued at 2210 million US$ in 2018 and will reach 5760 million US$ by the end of 2025, growing at a CAGR of 12.7% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Myelodysplastic Syndrome (MDS) Treatment market based on company, product type, end user and key regions.
This report studies the global market size of Myelodysplastic Syndrome (MDS) Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Myelodysplastic Syndrome (MDS) Treatment in these regions.
This research report categorizes the global Myelodysplastic Syndrome (MDS) Treatment market by top players/brands, region, type and end user. This report also studies the global Myelodysplastic Syndrome (MDS) Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd
Sandoz Inc
Dr Reddys Laboratories Limited
Pharmascience Inc
Accord Healthcare Ltd
Mylan N.V.
Market size by Product
Azacitidine
Lenalidomide
Decitabine
Deferasirox
Market size by End User
Refractory cytopenia with unilineage dysplasia
Refractory anemia with ringed sideroblasts
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Myelodysplastic Syndrome (MDS) Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Myelodysplastic Syndrome (MDS) Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Myelodysplastic Syndrome (MDS) Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Myelodysplastic Syndrome (MDS) Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Myelodysplastic Syndrome (MDS) Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Myelodysplastic Syndrome (MDS) Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Summary:
Get latest Market Research Reports on Myelodysplastic Syndrome (MDS) Treatment . Industry analysis & Market Report on Myelodysplastic Syndrome (MDS) Treatment is a syndicated market report, published as Global Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Myelodysplastic Syndrome (MDS) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.